

April 22, 2016

# MYOS Reports Positive Results From Fortetropin(R) Clinical Study

## Fortetropin Significantly Reduces Serum Myostatin Levels at a Dose Approximately 40% Lower Than the Current Recommended Dose; MYOS to Present Results From Clinical Study at International Conference on Frailty & Sarcopenia Research in April

CEDAR KNOLLS, NJ -- (Marketwired) -- 04/22/16 -- [MYOS RENS](#) Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging [biotherapeutics](#) and [bionutrition](#) company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the positive results of a recent clinical study which demonstrated that the daily use of 4 grams of Fortetropin, which is approximately 40% lower than the currently-recommended 6.6 grams dose, results in statistically significant decreases in serum myostatin levels. A plethora of evidence has linked decreases in serum myostatin levels with gains in lean muscle mass.

"We expect the positive results of this important clinical study to contribute to the success of our aggressive commercialization strategy for Fortetropin®," said Robert J. Hariri, M.D., Ph.D., Chairman of MYOS. Dr. Hariri continued, "at a dose as low as 4 grams per day in the broad population, along with exercise, Fortetropin may be beneficial for improving lean muscle mass, which has significant therapeutic benefits for overall health including bone density, control of serum glucose, triglyceride levels and reducing inflammation." The Company's abstract, entitled "A Dose-Ranging Study of the Natural Myostatin Reducing Agent, Fortetropin®, in Young Adult Males and Females" will be presented at the International Conference on Frailty & Sarcopenia Research to be held April 28-29, 2016 in Philadelphia. The clinical study, which was led by Jacob Wilson, Ph.D., CSCS\*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory at The University of Tampa, examined the effects of Fortetropin supplementation on serum myostatin levels at various dosing levels in young adult males and females. The purpose of this study was to enable MYOS to better define the dose response curve for Fortetropin, the minimal effective dose of Fortetropin and the effects of Fortetropin on serum myostatin. Co-authors of the clinical study from MYOS included Maghsoud Dariani, M.S., Head of Science & Technology, and Neerav D. Padliya, Ph.D., Vice President, Research Alliances.

### **About Fortetropin®**

Fortetropin® is a natural, myostatin reducing agent that is derived from fertilized chicken egg yolk using patented proprietary technology. Myostatin is a natural regulatory protein that inhibits the growth of new muscle tissue, and thus plays a central role in skeletal muscle health. In a double-blind, placebo-controlled trial conducted in 2014 at The University of Tampa to evaluate the effects of Fortetropin, Dr. Wilson observed a statistically significant decrease in serum myostatin levels in addition to an increase in muscle size and lean body mass in average males over a 12 week period while performing modest resistance training. Dr. Wilson commented, "The data from our 2014 study clearly demonstrated that Fortetropin

resulted in statistically significant muscle gains in recreationally-trained individuals at the recommended dose of 6.6 grams per day. Males taking daily supplements of Fortetropin and exercising twice a week showed impressive gains in muscle growth and lean body mass, which are both key components for overall health and longevity."

***About MYOS RENS Technology, Inc.***

MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin reducing agent. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit [www.myosrens.com](http://www.myosrens.com).

***Forward-Looking Statements***

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

**Company Contact**

MYOS RENS Technology Inc.  
Joseph DosSantos  
Chief Financial Officer  
MYOS RENS Technology Inc.  
(973) 509-0444

[Email Contact](#)

Investor Relations Contact

Michael Briola  
CEO  
Motion Communications, Inc.  
[Email Contact](#)  
(972) 646-3400

Source: MYOS RENS Technology Inc.